Abstract
Abstract 14702: The Burden of Cardiac Adverse Events Associated With Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Large Pharmacovigilance Database Analysis
Circulation (New York, N.Y.), Vol.146(S_1), p.A14702
11/08/2022
DOI: 10.1161/circ.146.suppl_1.14702
Abstract
Byline: Anuj Thakre, Internal Medicine, LSU Health Sciences Cntr Shreveport, Shreveport, LA; Akhilesh Babbili, Internal Medicine, LSU Health Sciences Cntr Shreveport, Shreveport, LA; Sahith Reddy Thotamgari, Internal Medicine, LSU Health Sciences Cntr Shreveport, Shreveport, LA; Udhayvir Grewal, Internal Medicine, LSU Health Sciences Cntr Shreveport, Shreveport, LA; Kavitha Beedupalli, Hematology and Oncology, LSU Health Sciences Cntr Shreveport, Shreveport, LA; Paari Dominic, Cardiology, LSU Health Sciences Cntr Shreveport, Shreveport, LA Introduction: Anaplastic Lymphoma Kinase tyrosine kinase inhibitors (ALK TKIs) have played a pivotal role in the management of Metastatic Non-Small-Cell Lung Cancer (NSCLC). ALK rearrangements are associated with improved survival compared to the standard first-line therapy. However, the cardiovascular safety profile of these agents remains understudied. Methods: We interrogated the Food and Drug Administration's Adverse Event Reporting System (FAERS) database for the reported cardiac adverse events (AE) of: crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. The number of cardiac AEs reported for ALK TKIs were compared with all the other drugs between 2011-2022. Disproportionality analysis was performed using Reporting Odds Ratio (ROR). Results: We identified a total of 20,337 AEs for ALK TKIs, of which 1191 were cardiac AEs. The most frequently reported cardiac AEs associated with ALK TKIs were pericardial diseases (271), followed by bradyarrhythmia (253) and heart failure (HF) (245). HF reporting was significantly higher with lorlatinib (ROR 2.9; CI 95% 2.0-4.1). Ceretinib was associated with significantly higher reporting of pericardial diseases (ROR 28.3; CI 95% 22.6-35.3), and other tachyarrhythmias (ROR 8.9; CI 95% 5.7-13.8). Alectinib was associated with significantly higher reporting of bradyarrhythmias (ROR 9.7, CI 95% 7.8-12.1). Conclusion: Cardiovascular AEs were disproportionately higher with ALK TKIs for pericardial diseases and bradyarrhythmias with ceretinib and alectinib respectively. Larger prospective studies are needed to identify high-risk groups that would benefit from robust cardiovascular surveillance.
Details
- Title: Subtitle
- Abstract 14702: The Burden of Cardiac Adverse Events Associated With Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: A Large Pharmacovigilance Database Analysis
- Creators
- Anuj ThakreAkhilesh BabbiliSahith Reddy ThotamgariUdhayvir GrewalKavitha BeedupalliPaari Dominic
- Resource Type
- Abstract
- Publication Details
- Circulation (New York, N.Y.), Vol.146(S_1), p.A14702
- Publisher
- Lippincott Williams & Wilkins, WK Health
- DOI
- 10.1161/circ.146.suppl_1.14702
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Language
- English
- Date published
- 11/08/2022
- Description audience
- Professional
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984367232002771
Metrics
4 Record Views